Literature DB >> 14610198

Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines.

Wing-Pui Kong1, Yue Huang, Zhi-Yong Yang, Bimal K Chakrabarti, Zoe Moodie, Gary J Nabel.   

Abstract

The ability to elicit an immune response to a spectrum of human immunodeficiency virus type 1 (HIV-1) gene products from divergent strains is a desirable feature of an AIDS vaccine. In this study, we examined combinations of plasmids expressing multiple HIV-1 genes from different clades for their ability to elicit humoral and cellular immune responses in mice. Immunization with a modified Env, gp145DeltaCFI, in combination with a Gag-Pol-Nef fusion protein plasmid elicited similar CD4(+) and CD8(+) cellular responses to immunization with either vector alone. Further, when mice were immunized with a mixture of Env from three clades, A, B, and C, together with Gag-Pol-Nef, the overall potency and balance of CD4(+)- and CD8(+)-T-cell responses to all viral antigens were similar, with only minor differences noted. In addition, plasmid mixtures elicited antibody responses comparable to those from individual inoculations. These findings suggest that a multigene and multiclade vaccine, including components from A, B, and C Env and Gag-Pol-Nef, can broaden antiviral immune responses without immune interference. Such combinations of immunogens may help to address concerns about viral genetic diversity for a prospective HIV-1 vaccine.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14610198      PMCID: PMC262562          DOI: 10.1128/jvi.77.23.12764-12772.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

Review 1.  Challenges and opportunities for development of an AIDS vaccine.

Authors:  G J Nabel
Journal:  Nature       Date:  2001-04-19       Impact factor: 49.962

2.  Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.

Authors:  D H Barouch; S Santra; J E Schmitz; M J Kuroda; T M Fu; W Wagner; M Bilska; A Craiu; X X Zheng; G R Krivulka; K Beaudry; M A Lifton; C E Nickerson; W L Trigona; K Punt; D C Freed; L Guan; S Dubey; D Casimiro; A Simon; M E Davies; M Chastain; T B Strom; R S Gelman; D C Montefiori; M G Lewis; E A Emini; J W Shiver; N L Letvin
Journal:  Science       Date:  2000-10-20       Impact factor: 47.728

3.  Use of overlapping peptide mixtures as antigens for cytokine flow cytometry.

Authors:  H T Maecker; H S Dunn; M A Suni; E Khatamzas; C J Pitcher; T Bunde; N Persaud; W Trigona; T M Fu; E Sinclair; B M Bredt; J M McCune; V C Maino; F Kern; L J Picker
Journal:  J Immunol Methods       Date:  2001-09-01       Impact factor: 2.303

4.  Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

Authors:  R R Amara; F Villinger; J D Altman; S L Lydy; S P O'Neil; S I Staprans; D C Montefiori; Y Xu; J G Herndon; L S Wyatt; M A Candido; N L Kozyr; P L Earl; J M Smith; H L Ma; B D Grimm; M L Hulsey; J Miller; H M McClure; J M McNicholl; B Moss; H L Robinson
Journal:  Science       Date:  2001-04-06       Impact factor: 47.728

5.  Interactions of single and combined human immunodeficiency virus type 1 (HIV-1) DNA vaccines.

Authors:  A Kjerrström; J Hinkula; G Engström; V Ovod; K Krohn; R Benthin; B Wahren
Journal:  Virology       Date:  2001-05-25       Impact factor: 3.616

6.  Protection from immunodeficiency virus challenges in rhesus macaques by multicomponent DNA immunization.

Authors:  J J Kim; J S Yang; L K Nottingham; D J Lee; M Lee; K H Manson; M S Wyand; J D Boyer; K E Ugen; D B Weiner
Journal:  Virology       Date:  2001-07-05       Impact factor: 3.616

Review 7.  Recombinant viruses as a tool for therapeutic vaccination against human cancers.

Authors:  M C Bonnet; J Tartaglia; F Verdier; P Kourilsky; A Lindberg; M Klein; P Moingeon
Journal:  Immunol Lett       Date:  2000-09-15       Impact factor: 3.685

8.  Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression.

Authors:  Y Huang; W P Kong ; G J Nabel
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

9.  Cytotoxic T lymphocytes recognize structurally diverse, clade-specific and cross-reactive peptides in human immunodeficiency virus type-1 gag through HLA-B53.

Authors:  L Dorrell; B E Willcox; E Y Jones; G Gillespie; H Njai; S Sabally; A Jaye; K DeGleria; T Rostron; E Lepin; A McMichael; H Whittle; S Rowland-Jones
Journal:  Eur J Immunol       Date:  2001-06       Impact factor: 5.532

10.  Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques.

Authors:  X Jin; D E Bauer; S E Tuttleton; S Lewin; A Gettie; J Blanchard; C E Irwin; J T Safrit; J Mittler; L Weinberger; L G Kostrikis; L Zhang; A S Perelson; D D Ho
Journal:  J Exp Med       Date:  1999-03-15       Impact factor: 14.307

View more
  45 in total

1.  A specific domain of the Chikungunya virus E2 protein regulates particle formation in human cells: implications for alphavirus vaccine design.

Authors:  Wataru Akahata; Gary J Nabel
Journal:  J Virol       Date:  2012-05-30       Impact factor: 5.103

Review 2.  Basic statistical considerations in virological experiments.

Authors:  Barbra A Richardson; Julie Overbaugh
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

3.  Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization.

Authors:  Wing-pui Kong; Ling Xu; Konrad Stadler; Jeffrey B Ulmer; Sergio Abrignani; Rino Rappuoli; Gary J Nabel
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

4.  Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens.

Authors:  Lan Wu; Wing-Pui Kong; Gary J Nabel
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

5.  Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41.

Authors:  Franck Lemiale; Hedi Haddada; Gary J Nabel; Douglas E Brough; C Richter King; Jason G D Gall
Journal:  Vaccine       Date:  2006-11-28       Impact factor: 3.641

6.  Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: utility for detection of diverse HIV-1 subtypes.

Authors:  Surender Khurana; James Needham; Susan Park; Bonnie Mathieson; Michael P Busch; George Nemo; Phillipe Nyambi; Susan Zolla-Pazner; Suman Laal; Joseph Mulenga; Elwyn Chomba; Eric Hunter; Susan Allen; James McIntyre; Indira Hewlett; Sherwin Lee; Shixing Tang; Elliot Cowan; Chris Beyrer; Marcus Altfeld; Xu G Yu; Anatole Tounkara; Ousmane Koita; Anatoli Kamali; Nga Nguyen; Barney S Graham; Deborah Todd; Peter Mugenyi; Omu Anzala; Eduard Sanders; Nzeera Ketter; Patricia Fast; Hana Golding
Journal:  J Acquir Immune Defic Syndr       Date:  2006-11-01       Impact factor: 3.731

7.  Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs.

Authors:  Yuuei Shu; Sarah Winfrey; Zhi-Yong Yang; Ling Xu; Srinivas S Rao; Indresh Srivastava; Susan W Barnett; Gary J Nabel; John R Mascola
Journal:  Vaccine       Date:  2006-11-07       Impact factor: 3.641

Review 8.  Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business".

Authors:  Kimberly A Schoenly; David B Weiner
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

9.  A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses.

Authors:  Elizabeth S Gabitzsch; Younong Xu; Lois H Yoshida; Joseph Balint; Richard B Gayle; Andrea Amalfitano; Frank R Jones
Journal:  Immunol Lett       Date:  2008-12-13       Impact factor: 3.685

Review 10.  Viral sequence diversity: challenges for AIDS vaccine designs.

Authors:  Sean P McBurney; Ted M Ross
Journal:  Expert Rev Vaccines       Date:  2008-11       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.